Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.
Myeloid-derived suppressor cells (MDSCs) are a well-defined population of cells that accumulate in the tissue of tumor-bearing animals and are known to inhibit immune responses. Within 4 days, bone marrow cells cultured in granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor resulted in the generation of CD11b(+)Ly6G(lo)Ly6C(+) MDSCs, the majority of which are interleukin-4Rα (IL-4Rα(+)) and F4/80(+). Such MDSCs potently inhibited in vitro allogeneic T-cell responses. Suppression was dependent on L-arginine depletion by arginase-1 activity. Exogenous IL-13 produced an MDSC subset (MDSC-IL-13) that was more potently suppressive and resulted in arginase-1 up-regulation. Suppression was reversed with an arginase inhibitor or on the addition of excess L-arginine to the culture. Although both MDSCs and MDSC-IL-13 inhibited graft-versus-host disease (GVHD) lethality, MDSC-IL-13 were more effective. MDSC-IL-13 migrated to sites of allopriming. GVHD inhibition was associated with limited donor T-cell proliferation, activation, and proinflammatory cytokine production. GVHD inhibition was reduced when arginase-1-deficient MDSC-IL-13 were used. MDSC-IL-13 did not reduce the graft-versus-leukemia effect of donor T cells. In vivo administration of a pegylated form of human arginase-1 (PEG-arg1) resulted in L-arginine depletion and significant GVHD reduction. MDSC-IL-13 and pegylated form of human arginase-1 represent novel strategies to prevent GVHD that can be clinically translated.
Highfill
Steven L
SL
University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
Rodriguez
Paulo C
PC
Zhou
Qing
Q
Goetz
Christine A
CA
Koehn
Brent H
BH
Veenstra
Rachelle
R
Taylor
Patricia A
PA
Panoskaltsis-Mortari
Angela
A
Serody
Jonathan S
JS
Munn
David H
DH
Tolar
Jakub
J
Ochoa
Augusto C
AC
Blazar
Bruce R
BR
D000818:Animals; D001119:Arginase / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism; D016026:Bone Marrow Transplantation; D002478:Cells, Cultured; D006086:Graft vs Host Disease / Q000201:enzymology / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D015151:Immunoblotting; D018793:Interleukin-13 / Q000494:pharmacology*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D017346:Protein Serine-Threonine Kinases / Q000502:physiology; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D015854:Up-Regulation
D018793:Interleukin-13; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C070634:Eif2ak4 protein, mouse; D017346:Protein Serine-Threonine Kinases; D001119:Arginase
Blood. 2000 Nov 1;96(9):2973-80
11049973
J Exp Med. 2000 Oct 2;192(7):1027-34
11015443
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7
19346489
Curr Opin Chem Biol. 1999 Apr;3(2):226-35
10226050
J Nutr. 2004 Oct;134(10 Suppl):2760S-2764S; discussion 2765S-2767S
15465781
J Biol Chem. 2002 Jun 14;277(24):21123-9
11950832
Cancer Res. 2007 Jan 1;67(1):309-17
17210712
Blood. 2009 Jul 16;114(3):693-701
19458354
Cancer Res. 2005 Apr 15;65(8):3044-8
15833831
J Immunol. 1998 Jun 1;160(11):5347-54
9605134
Cancer Res. 2004 Aug 15;64(16):5839-49
15313928
Blood. 2004 Dec 1;104(12):3804-12
15292057
J Clin Invest. 2007 May;117(5):1147-54
17476344
Cancer Res. 2006 Jan 15;66(2):1123-31
16424049
Stem Cells. 2010 Mar 31;28(3):620-32
20073041
J Biol Chem. 1998 Aug 28;273(35):22635-9
9712892
J Immunol. 2003 Aug 1;171(3):1232-9
12874210
Immunity. 2005 May;22(5):633-42
15894280
Nat Rev Immunol. 2005 Aug;5(8):641-54
16056256
Cancer Immunol Immunother. 2010 Jan;59(1):47-62
19449184
Chem Biol Interact. 1995 May 19;96(2):203-6
7728908
Blood. 2008 Apr 15;111(8):4233-44
18272812
J Immunol. 2008 Oct 15;181(8):5791-802
18832739
Adv Exp Med Biol. 2007;601:213-23
17713008
Blood. 2007 Feb 15;109(4):1568-73
17023580
J Immunol. 2004 Dec 15;173(12):7324-30
15585856
J Clin Invest. 2006 Oct;116(10):2777-90
17016559
J Immunol. 2004 Jan 15;172(2):989-99
14707072
J Immunol. 1999 May 15;162(10):5728-37
10229805
Blood. 2010 Jun 24;115(25):5214-21
20407034